Quoin Pharmaceuticals, Ltd. Stock

Equities

QNRX

US74907L3006

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-07-12 pm EDT 5-day change 1st Jan Change
0.656 USD +0.92% Intraday chart for Quoin Pharmaceuticals, Ltd. +13.12% -86.63%
Sales 2024 * - Sales 2025 * - Capitalization 2.61M
Net income 2024 * -7M Net income 2025 * -11M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.19 x
P/E ratio 2025 *
-0.7 x
Employees 4
Yield 2024 *
-
Yield 2025 *
-
Free-Float 24.32%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.92%
1 week+13.12%
Current month+13.10%
1 month-8.89%
3 months-11.47%
6 months-85.23%
Current year-86.63%
More quotes
1 week
0.57
Extreme 0.57
0.68
1 month
0.57
Extreme 0.57
0.70
Current year
0.57
Extreme 0.57
6.18
1 year
0.57
Extreme 0.57
12.00
3 years
0.57
Extreme 0.57
2 018.25
5 years
0.57
Extreme 0.57
2 018.25
10 years
0.57
Extreme 0.57
2 018.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 18-03-04
Founder 55 18-03-04
Director of Finance/CFO 60 21-10-31
Members of the board TitleAgeSince
Director/Board Member - 21-10-27
Director/Board Member 73 21-10-27
Director/Board Member 66 21-10-27
More insiders
Date Price Change Volume
24-07-12 0.656 +0.92% 28,493
24-07-11 0.65 +7.21% 34,837
24-07-10 0.6063 +1.39% 47,549
24-07-09 0.598 +3.09% 42,385
24-07-08 0.5801 +0.03% 33,504

Delayed Quote Nasdaq, July 12, 2024 at 04:30 pm EDT

More quotes
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.656 USD
Average target price
5.483 USD
Spread / Average Target
+735.87%
Consensus